Gaithersburg, United States
MedGene Therapeutics, Inc., founded in 2015 and headquartered in MD, USA, is a cutting-edge biotech startup specialized in T cell immunotherapy targeting solid tumor cancers. Despite the longstanding challenge of using T cell therapy on solid tumors, MedGene is breaking ground with its proprietary technologies—licensed PBL-T from the NIH and collaborative development of RIV-8 with Seoul National University.
Positioned in the intersection of Biotechnology and Health Care industries, MedGene uses an innovative T cell replication and enrichment method to bolster the body’s cancer defenses. Their platform represents years of meticulous R&D, potentially setting new benchmarks in cancer treatment effectiveness.
The company garnered a $1.10M Seed Round investment on June 25, 2021, underscoring investor confidence in their technological edge and market potential. With its slogan "Better life through better science," MedGene is poised to be a transformative player in cancer therapeutics.
